Table 2.
Primary and secondary endpoints.
| Primary endpoint: | |
| Incidence of severe hepatotoxicity | 10.7% (6/56 Patients) |
| Secondary endpoints | |
| NNRTIs | 3 cases/1203 months |
| 0.249 cases per 100 months of exposure | |
| Efavirenz | 2 cases/923 months |
| 0.217 cases per 100 months of exposure | |
| Nevirapine | 1 case/280 months |
| 0.357 cases per 100 months of exposure | |
| PIs | 3 cases/996 months |
| 0.301 cases per 100 months of exposure | |
| Indinavir | 1 case/97 months |
| 1.03 cases per 100 months of exposure | |
| Nelfinavir | 1 case/169 months |
| 0.592 cases per 100 months of exposure | |
| Saquinavir/Ritonavir | 1 case/100 months |
| 1.00 cases per 100 months of exposure |